Loading...
Market
Story
FDA Places Clinical Hold on Novavax's COVID-19 and Flu Vaccine Candidates, Shares Drop 20%
Oct 16, 2024, 01:21 PM
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Novavax's COVID-19 and influenza combination vaccine, as well as its standalone influenza vaccine candidates. The hold was prompted by a serious adverse event (SAE) reported in a trial participant, which involved motor neuropathy. Following the announcement, Novavax shares experienced a significant decline, dropping by as much as 20%, with a notable 16% and 18.7% drop at different points. The clinical hold aims to address safety concerns and ensure the well-being of trial participants.
View original story
Similar markets
Increase by more than 20% • 25%
Increase by 0-20% • 25%
Decrease by 0-20% • 25%
Decrease by more than 20% • 25%
Increases by 10% or more • 25%
Decreases by 10% or more • 25%
Remains within 10% of current value • 25%
Other outcome • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
No change or decrease • 25%
Decrease by more than 10% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Outperforms S&P 500 • 25%
Matches S&P 500 • 25%
Underperforms S&P 500 • 25%
Declines • 25%